SCHEMBL1490750

SCHEMBL1490750

CCOC(=O)C1[CH]C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7330352 1.00
SCHEMBL30676805 0.86
SCHEMBL2301530 0.84 ALDH1A1 (0.37)
SCHEMBL2533154 0.82
SCHEMBL8880070 0.82
SCHEMBL13969444 0.80 ALDH1A1 (0.37)
SCHEMBL17054628 0.80 ALDH1A1 (0.33)
SCHEMBL24471528 0.77 ALDH1A1 (0.38)
SCHEMBL11688026 0.77 PPM1B (0.46)
SCHEMBL14514261 0.77 ALDH1A1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3998261-A1 PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS Denali Therapeutics Inc. (US) 2022-05-18 EP claimed
EP-3697789-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2020-08-26 EP claimed
CN-111542526-A Condensed imidazole derivatives substituted by tertiary hydroxyl group as PI 3K-gamma inhibitor 因赛特公司 2020-08-14 CN claimed
CN-110804016-A Diaryl quinoline derivatives against mycobacterium tuberculosis 福建省微生物研究所 2020-02-18 CN claimed
WO-2019079469-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2019-04-25 WO claimed
EP-3472153-A1 PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS Denali Therapeutics Inc. (US) 2019-04-24 EP claimed
CN-105980387-B Serine/threonine kinase inhibitor 阵列生物制药公司 2019-04-19 CN claimed
US-20180208582-A1 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2018-07-26 US claimed
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP claimed
WO-2017218843-A1 PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS DENALI THERAPEUTICS INC. (US) 2017-12-21 WO claimed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 EP claimed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 US claimed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 WO claimed
EP-1685129-A4 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2008-10-22 EP claimed
CN-1906193-A Oxime substituted imidazo ring compounds 3M INNOVATIVE PROPERTIES CO (US) 2007-01-31 CN claimed
EP-1685129-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M Innovative Properties Company (US) 2006-08-02 EP claimed
WO-2005048933-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 WO claimed
US-6534503-B1 Treating sexual dysfunction, such as erectile dysfunction or sexual arousal disorder, with a compound having the generic formula X1-X2-(D)Phe-Arg-(D)Trp-X3. A particularly useful compound is HP-228, which has the formula LION BIOSCIENCE AG (DE) 2003-03-18 US claimed
EP-1214330-A1 BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-06-19 EP claimed
WO-2001021634-A1 BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-03-29 WO claimed